The impossible is simply what hasn’t been achieved yet. Cognitive Synergy Corporation's research and development program is focused on what’s next. By integrating innovation, rigorous evaluation, and translational science, we strive to turn possibility into progress—and progress into life-changing treatments.
Integrated Drug Discovery
01. Our Approach
We believe Alzheimer’s disease requires more than single-pathway treatments. Our lead investigational small molecule is designed to simultaneously reduce toxic amyloid and tau pathology while restoring synaptic integrity. By targeting the root drivers of neurodegeneration, we aim to deliver therapies that go beyond symptom management toward true disease modification.
02. Breakthrough Findings
In rigorous preclinical models, our small molecule reduced amyloid plaques and tau pathology, suppressed neuroinflammation, and restored synaptic proteins such as PSD-95, synaptophysin, and synapsin. Notably, the compound enhanced synaptic health even in non-diseased models, highlighting its unique potential to strengthen cognitive resilience. These results provide a compelling rationale for advancing toward clinical development.
Alzheimer's Disease
Early-to-mild Alzheimer’s disease (AD)
Pre-Clinical
70%
03. Path to Clinic
Our research program integrates translational biomarkers, pharmacology, and behavioral outcomes to ensure human relevance. With a robust preclinical package, favorable oral pharmacokinetics, and validated safety panels, Cognitive Synergy Corporation is progressing our small molecule through IND-enabling studies. Our goal is to rapidly advance into early clinical trials to bring hope to patients and families living with Alzheimer’s disease.
Who We Are
Cognitive Synergy Corporation is a biotechnology company pioneering novel small-molecule therapies for Alzheimer’s disease and other neurodegenerative disorders. Our mission is to transform treatment by addressing the root causes of disease—not just the symptoms. We unite cutting-edge science, translational biomarkers, and collaborative partnerships to build a robust drug development pipeline. Our lead candidate, has shown the ability to reduce amyloid and tau pathology while restoring synaptic health, positioning it as a potential first-in-class, disease-modifying therapy. At CSC, we are guided by innovation, scientific rigor, and an unwavering commitment to patients and families. We believe that by advancing cognitive health through synergy in science, we can change the future of Alzheimer’s disease.
Vision
At Cognitive Synergy Corporation, our vision is to change the future of Alzheimer’s disease by delivering therapies that not only slow progression but also restore cognitive health. We aspire to move beyond incremental advances and create the first truly disease-modifying treatment for patients and families worldwide.